Sylvester Comprehensive Cancer Center

  • HEAT - Abramowitz, Matthew

  • Investigator:
    Matthew Abramowitz
    RCname Email

    Coordinator:
    RCemailImg Milad Al Troudy El Troudi
    RCphone +1 (305) 2435620

    IRB: 20110491

    SDG: Radiation Oncology
    Disease Site(s):

    Prostate

    Sponsor: PROSTATE CANCER FOUNDATION

    Enrolling Sites:

    Deerfield
    Gables
    Northern Sydney Local Health District
    Sylvester
    University Hospital Trust of Turin

    Title:

    A Randomized Study of Radiation Hypofractionation via Extended versus Accelerated Therapy (HEAT) For Prostate Cancer

    Eligibility Criteria - NCT01794403 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221263 - Abramowitz Matthew

  • Investigator:
    Matthew Abramowitz
    RCname Email

    Coordinator:

    IRB: 20221263

    SDG: Radiation Oncology
    Disease Site(s):

    Other Skin

    Sponsor: ALPHA TAU MED LTD

    Enrolling Sites:

    Deerfield
    Sylvester

    Title:

    A Prospective International Multicenter, Pivotal, Single Arm, Open Label Clinical Study to Assess the Efficacy and Safety of Intratumoral Alpha DaRT224 for the Treatment of Patients with Recurrent Cutaneous Squamous Cell Carcinoma

    Eligibility Criteria - NCT05323253 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220843 - Azzam Gregory

  • Investigator:
    Gregory Azzam
    RCname Email

    Coordinator:

    IRB: 20220843

    SDG: Radiation Oncology
    Disease Site(s):

    Brain and Nervous System

    Sponsor: ETCTN

    Enrolling Sites:

    Sylvester

    Title:

    A Phase I/II Study of Nivolumab plus or minus Ipilimumab in Combination with Multi-fraction Stereotactic Radiosurgery for Recurrent High-grade Radiation-relapsed Meningioma

    Eligibility Criteria - NCT03604978 *This information has been extracted from " www.clinicaltrials.gov"

  • 20221026 - Azzam Gregory

  • Investigator:
    Gregory Azzam
    RCname Email

    Coordinator:

    IRB: 20221026

    SDG: Radiation Oncology
    Disease Site(s):

    Lung

    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    Phase III Trial of Stereotactic Radiosurgery (SRS) versus Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) for 10 or fewer Brain Metastases from Small Cell Lung Cancer

    Eligibility Criteria - NCT04804644 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220162 - Jin William

  • Investigator:
    William Jin
    RCname Email

    Coordinator:
    RCemailImg Zaida Abreu
    RCphone +1 (305) 2434243

    IRB: 20220162

    SDG: Radiation Oncology
    Disease Site(s):

    Multiple

    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    Phase III Randomized Trial of Proton Beam Therapy (PBT) Versus Intensity Modulated Photon Radiotherapy (IMRT) for the Treatment of Esophageal Cancer

    Eligibility Criteria - NCT03801876 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230828 - Kubicek Gregory

  • Investigator:
    Gregory Kubicek
    RCname Email

    Coordinator:

    IRB: 20230828

    SDG: Radiation Oncology
    Disease Site(s):

    Sponsor: CCTG

    Enrolling Sites:

    Sylvester

    Title:

    SPECT-CT Guided Elective Contralateral Neck Treatment (Select) For Patients With Lateralized Oropharyngeal Cancer: A Phase III Randomized Controlled Trial

    Eligibility Criteria - NCT05451004 *This information has been extracted from " www.clinicaltrials.gov"

  • MAVERICK - Libardi Dal Pra, Alan

  • Investigator:
    Alan Libardi Dal Pra
    RCname Email

    Coordinator:

    IRB: 20200727

    SDG: Radiation Oncology
    Disease Site(s):

    Lung

    Sponsor: SWOG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    MRI Brain Surveillance Alone Versus MRI Surveillance and Prophylactic Cranial Irradiation (PCI): A Randomized Phase III Trial in Small-Cell Lung Cancer (MAVERICK)

    Eligibility Criteria - NCT04155034 *This information has been extracted from " www.clinicaltrials.gov"

  • NRG-BN003 - Mellon, Eric

  • Investigator:
    Eric Mellon
    RCname Email

    Coordinator:

    IRB: 20170631

    SDG: Radiation Oncology
    Disease Site(s):

    Brain and Nervous System

    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    JMH
    Sylvester

    Title:

    NRG-BN003:Phase III Trial Of Observation Versus Irradiation For A Gross Totally Resected Grade II Meningioma

    Eligibility Criteria - NCT03180268 *This information has been extracted from " www.clinicaltrials.gov"

  • CCTG CE.7 - Mellon, Eric

  • Investigator:
    Eric Mellon
    RCname Email

    Coordinator:
    RCemailImg Lilly Sanchez
    RCphone +1 (305) 2430974

    IRB: 20190176

    SDG: Radiation Oncology
    Disease Site(s):

    Multiple

    Sponsor: CCTG

    Enrolling Sites:

    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    CCTG CE.7: A Phase III Trial of Stereotactic Radiosurgery Compared With Hippocampal-Avoidant Whole Brain Radiotherapy (HA-WBRT) Plus Memantine for 5 or More Brain Metastases

    Eligibility Criteria - NCT03550391 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210335 - Mellon Eric

  • Investigator:
    Eric Mellon
    RCname Email

    Coordinator:

    IRB: 20210335

    SDG: Radiation Oncology
    Disease Site(s):

    Brain and Nervous System

    Sponsor: SCCC

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    Pilot trial of spectroscopic MRI-guided, dose-escalated proton radiation therapy and bevacizumab for recurrent glioblastoma

    Eligibility Criteria - NCT05284643 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230556 - Mellon Eric

  • Investigator:
    Eric Mellon
    RCname Email

    Coordinator:

    IRB: 20230556

    SDG: Radiation Oncology
    Disease Site(s):

    Brain and Nervous System

    Sponsor: NRG

    Enrolling Sites:

    Sylvester

    Title:

    Protocol NRG-BN012, A Randomized Phase III Trial of Pre-Operative Compared to Post-Operative Stereotactic Radiosurgery in Patients with Resectable Brain Metastases (NCT05438212)

    Eligibility Criteria - NCT05438212 *This information has been extracted from " www.clinicaltrials.gov"

  • DECREASE - Portelance, Lorraine

  • Investigator:
    Lorraine Portelance
    RCname Email

    Coordinator:

    IRB: 20191276

    SDG: Radiation Oncology
    Disease Site(s):

    Anus

    Sponsor: ECOG

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    A Randomized Phase II Study De-Intensified ChemoRadiation for Early-Stage Anal Squamous Cell Carcinoma (DECREASE)

    Eligibility Criteria - NCT04166318 *This information has been extracted from " www.clinicaltrials.gov"

  • 20210172 - Portelance Lorraine

  • Investigator:
    Lorraine Portelance
    RCname Email

    Coordinator:
    RCemailImg Samantha St. Armand
    RCphone +1 (305) 2432006

    IRB: 20210172

    SDG: Radiation Oncology
    Disease Site(s):

    Rectum

    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Kendall
    Plantation
    Sylvester

    Title:

    Selective Treatment with Magnetic Resonance Image Guided Pelvic Adaptive Radiation Therapy Combined with Total Neoadjuvant ChemoTherapy for the Conservative Management of Locally Advanced Rectal Cancer

    Eligibility Criteria - NCT05412082 *This information has been extracted from " www.clinicaltrials.gov"

  • 20231278 - Rich Benjamin

  • Investigator:
    Benjamin Rich
    RCname Email

    Coordinator:

    IRB: 20231278

    SDG: Radiation Oncology
    Disease Site(s):

    Prostate

    Sponsor: SCCC

    Enrolling Sites:

    Aventura
    Coral Springs
    Deerfield
    Gables
    Plantation
    Sylvester

    Title:

    A Phase II Trial of PSMA-Directed Para-Aortic Radiation Therapy for Oligorecurrent Prostate Cancer ? The OCEAN Trial

    Eligibility Criteria - NCT06392295 *This information has been extracted from " www.clinicaltrials.gov"

  • SABER Study - Takita, Cristiane

  • Investigator:
    Cristiane Takita
    RCname Email

    Coordinator:

    IRB: 20190283

    SDG: Radiation Oncology
    Disease Site(s):

    Breast

    Sponsor: SCCC

    Enrolling Sites:

    Sylvester

    Title:

    Phase I Study to Evaluate the Safety and Feasibility of Preoperative Ablative Breast Radiotherapy (SABER) for Selected Early Stage Breast Cancer

    Eligibility Criteria - NCT04360330 *This information has been extracted from " www.clinicaltrials.gov"

  • MA.39: TAILOR RT - Takita, Cristiane

  • Investigator:
    Cristiane Takita
    RCname Email

    Coordinator:
    RCemailImg Samantha St. Armand
    RCphone +1 (305) 2432006

    IRB: 20190405

    SDG: Radiation Oncology
    Disease Site(s):

    Breast

    Sponsor: CCTG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    CCTG MA.39: A Randomized Trial of Regional Radiotherapy in Biomarker Low Risk Node Positive Breast Cancer

    Eligibility Criteria - NCT03488693 *This information has been extracted from " www.clinicaltrials.gov"

  • 20220017 - Takita Cristiane

  • Investigator:
    Cristiane Takita
    RCname Email

    Coordinator:
    RCemailImg Samantha St. Armand
    RCphone +1 (305) 2432006

    IRB: 20220017

    SDG: Radiation Oncology
    Disease Site(s):

    Breast

    Sponsor: NRG

    Enrolling Sites:

    Deerfield
    Gables
    Sylvester

    Title:

    A Phase III Clinical Trial Evaluating De-Escalation Of Breast Radiation For Conservative Treatment Of Stage I, Hormone Sensitive, HER2-Negative, Oncotype Recurrence Score = 18 Breast Cancer

    Eligibility Criteria - NCT04852887 *This information has been extracted from " www.clinicaltrials.gov"

  • 20230815 - Yechieli Raphael

  • Investigator:
    Raphael Yechieli
    RCname Email

    Coordinator:

    IRB: 20230815

    SDG: Radiation Oncology
    Disease Site(s):

    Lung

    Sponsor: Alliance

    Enrolling Sites:

    Aventura
    Deerfield
    Gables
    Sylvester

    Title:

    A Randomized Phase II/III Trial of Modern Immunotherapy Based Systemic Therapy with or without SBRT for PD-L1-Negative, Advanced Non-small Cell Lung Cancer

    Eligibility Criteria - NCT04929041 *This information has been extracted from " www.clinicaltrials.gov"